Paraoxonase polymorphisms and toxicity of organophosphates

Toxicology of Organophosphate & Carbamate Compounds

Volumn , Issue , 2006, Pages 247-255

  Costa, Lucio G ^a   Cole, Toby B ^a   Vitalone, Annabella ^b   Furlong, Clement E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845953603     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088523-7/50019-3     Document Type: Chapter

References (78)

1. Adkins S., Gan K.N., Mody M., LaDu B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 1993, 53:598-608.
2. Aldridge W.N. Serum esterases I. Two types of esterase (A and B) hydrolyzing p-nitrophenyl acetate, proprionate and butyrate and a method for their determination. Biochem. J. 1953, 53:110-117.
3. Augustinsson K.B., Barr M. Age variation in plasma arylesterase activity in children. Clin. Chim. Acta 1963, 8:568-573.
4. Benke G.M., Murphy S.D. The influence of age in the toxicity and metabolism of methylparathion and parathion in male and female rats. Toxicol. Appl. Pharmacol. 1975, 31:254-269.
5. Berkowitz G.S., Wetmur J.G., Birman-Deych E., Obel J., Lapinski R.H., Godbold J.H., Holzman I.R., WolffM.S. In utero pesticide exposure, meternal paraoxonase activity, and head circumference. Environ. Health Perspect. 2004, 112:388-391.
6. Blatter Garin M.C., James R.W., Dussoix P., Blanche M., Passa P., Froguel P., Ruiz J. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 1997, 99:62-66.
7. Brealey C.B., Walker C.M., Baldwin B.C. A-esterase activities in relation to the differential toxicity of pirimiphos-methyl to birds and mammals. Pestic. Sci. 1980, 11:546-554.
8. Brophy V.H., Hastings M.D., Clendenning J.B., Richter R.J., Jarvik J.P., Furlong C.E. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001, 11:77-84.
9. Brophy V.H., Jampsa R.L., Clendenning J.B., McKinstry L.A., Furlong C.E. Effects of 5' regulatory-region polymorphisms on paraoxonase gene (PON1) expression. Am. J. Hum. Genet. 2001, 68:1428-1436.
10. Brophy V.H., Jarvik G.P., Furlong C.E. PON1 polymorphisms. Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects 2002, 53-77. Kluwer, Norwell, MA. L.G. Costa, C.E. Furlong (Eds.).
11. Chambers J.E., Ma R., Boone J.S., Chambers H.W. Role of detoxication pathways in acute toxicity of phosphorothioate insecticides in the rat. Life Sci 1994, 54:1357-1364.
12. Chen J., Kumar M., Chan W., Berkowitz G.S., Wetmur J.G. Increased influence of genetic variation on PON1 activity in neonates. Environ. Health Perspect. 2003, 111:1403-1410.
13. Cherry N., Mackness M.I., Durrington P., Povey A., Dippnall M., Smith T., Mackness B. Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet 2002, 359:763-764.
14. Cole T.B., Jampsa R.L., Walter B.J., Arndt T.L., Richter R.J., Shih D.M., Tward A., Lusis A.J., Jack R.M., Costa L.G., Furlong C.E. Expression of human paraoxonase during development. Pharmacologenetics 2003, 13:1-8.
15. Cole T.B., Walter B.J., Shih D.M., Tward A.D., Lusis A.J., Timchalk C., Richter R.J., Costa L.G., Furlosy C.E. Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonese (PON1) Q192R polymorphism. Pharmacogenet. Genomics 2005, 15:589-598.
16. Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects 2002, Kluwer, Norwell, MA. L.G. Costa, C.E. Furlong (Eds.).
17. Costa L.G., Richter R.J., Murphy S.D., Omenn G.S., Motulsky A.G., Furlong C.E. Species differences in serum paraoxonase correlate with sensitivity to paraoxon toxicity. Toxicology of Pesticides: Experimental, Clinical and Regulatory Perspectives 1987, 263-266. Springer-Verlag, Heidelberg. L.G. Costa, C.L. Galli, S.D. Murphy (Eds.).
18. Costa L.G., McDonald B.E., Murphy S.D., Omenn G.S., Richter R.J., Motulsky A.G., Furlong C.E. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol. Appl. Pharmacol. 1990, 103:66-76.
19. Costa L.G., Li W.F., Richter R.J., Shih D.M., Lusis A.J., Furlong C.E. PON1 and organophosphate toxicity. Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects 2002, 165-183. Kluwer, Norwell, MA. L.G. Costa, C.E. Furlong (Eds.).
20. Costa L.G., Cole T.B., Jarvik G.P., Furlong C.E. Functional genomics of the paraoxonase (PON1) polymorphisms: Effect on pesticide sensitivity, cardiovascular disease and drug metabolism. Annu. Rev. Med. 2003, 54:371-392.
21. Costa L.G., Cole T.B., Furlong C.E. Polymorphisms of paraoxonase (PON1) and their significance in clinical toxicology of organophosphate. J. Toxicol. Clin. Toxicol. 2003, 41:37-45.
22. Costa L.G., Vitalone A., Cole T.B., Furlong C.E. Modulation of paraoxonase activity. Biochem. Pharmacol. 2005, 69:541-550.
23. Cowan J., Sinton C.M., Varley A.W., Wians F.H., Haley R.W., Munford R.S. Gene therapy to prevent organophosphate intoxication. Toxicol. Appl. Pharmacol. 2001, 173:1-6.
24. Davies H., Richter R.J., Kiefer M., Broomfield C., Sowalla J., Furlong C.E. The human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genet. 1996, 14:334-336.
25. Deakin S., Leviev I., Gomeraschi M., Calabresi L., Franceschini G., James R.W. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high-affinity, saturable, desorption mechanism. J. Biol. Chem. 2002, 277:4301-4308.
26. Draganov D.I., La Du B.N. Pharmacogenetics of paraoxonases: A brief review. Naunyn-Schmiedeberg's Arch. Pharmacol. 2004, 369:78-88.
27. Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2001, 21:473-480.
28. Eckerson H.W., Wyte C.M., LaDu B.N. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 1983, 35:1126-1138.
29. Ecobichon D.J., Stephens D.S. Perinatal development of human blood esterases. Clin. Pharmacol. Ther. 1973, 14:41-47.
30. Furlong C.E. PON1 status and neurologic symptom complexes in Gulf War veterans. Genome Res. 2000, 10:153-155.
31. Furlong C.E., Richter R.J., Chapline C., Crabb J.W. Purification of rabbit and human serum paraoxonase. Biochemistry 1991, 30:10133-10140.
32. Furlong C.E., Li W.F., Richter R.J., Shih D.M., Lusis A.J., Alleva E., Costa L.G. Genetic and temporal determinants of pesticide sensitivity: Role of paraoxonase (PON1). Neurotoxicology 2000, 21:91-100.
33. Gan K.N., Smolen A.L., Eckerson H.W., LaDu B.N. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 1991, 19:100-106.
34. Haley R.W., Billecke S., LaDu B.N. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol. Appl. Pharmacol. 2000, 157:227-233.
35. Harbison R.D. Perinatal development of human blood esterases. Clin. Pharmacol. Ther. 1975, 14:41-47.
36. Harel M., Aharoni A., Gaidukov L., Brumshtein B., Khersonsky O., Meged R., Dvir H., Revelli R.B.G., McCarthy A., Toker L., Silman I., Sussman J.L., Tawfik D.S. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nature Struct. Mol. Biol. 2004, 11:412-419.
37. Hassett C., Richter R.J., Humbert R., Chapline C., Crabb J.W., Omiecinski C.J., Furlong C.E. Characterization of DNA clones encoding rabbit and human serum paraoxonase: The mature protein retains its signal sequence. Biochemistry 1991, 30:10141-10149.
38. Hernandez A.F., Mackness B., Rodrigo L., Lopez O., Pla A., Gil F., Durrington P.N., Pena G., Passon T., Serrano J.L., Mackness M.I. Paraoxonase activity and genetic polymorphisms in greenhouse workers with long term pesticide exposure. Hum. Exp. Toxicol. 2003, 22:565-574.
39. Hotopf M., Mackness M.I., Nikolau V., Collier D.A., Curtis C., David A., Durrington P., Hull L., Ismail K., Peekman M., Unwin C., Wessely S., Mackness B. Paraoxonase in Persian Gulf veterans. J. Occup. Environ. Med. 2003, 45:668-675.
40. Humbert R., Adler D.A., Disteche C.M., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase polymorphisms. Nature Genet. 1993, 3:73-76.
41. Institute of Medicine Gulf War and Health: Vol. 1. Depleted Uranium, Pyridostigmine Bromide, Sarin, Vaccines 2000, National Academy Press, Washington, DC.
42. Institute of Medicine Gulf War and Health: Vol. 2. Insecticides and Solvents 2003, National Academy Press, Washington, DC.
43. 55 genotype. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2441-2447.
44. Jarvik G.P., Jampsa R., Richter R.J., Carlson C.S., Rieder M.G., Nickerson D.A., Furlong C.E. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics 2003, 13:291-295.
45. Karanth S., Pope C. Carboxylesterase and A-esterase activities during maturation and aging: Relationship to the toxicity of chlorpyrifos and parathion in rats. Toxicol. Sci. 2000, 58:282-289.
46. Lee B.W., London L., Poulauskis J., Myers J., Christiani D.C. Association between human paraoxonase gene polymorphism and chronic symptoms in pesticide-exposed workers. J. Occup. Environ. Med. 2003, 45:118-122.
47. Leview I., James R.W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 2000, 20:516-521.
48. Li W.F., Costa L.G., Furlong C.E. Serum paraoxonase status: A major factor in determinig resistance to organophosphates. J. Toxicol. Environ. Health 1993, 40:337-346.
49. Li W.F., Furlong C.E., Costa L.G. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol. Lett. 1995, 76:219-226.
50. Li W.F., Matthews C., Disteche C.M., Costa L.G., Furlong C.E. Paraoxonase (PON1) gene in mice: Sequencing, chromosomal localization and developmental expression. Pharmacogenetics 1997, 7:137-144.
51. Li W.F., Costa L.G., Richter R.J., Hagen T., Shih D.M., Tward A., Lusis A.J., Furlong C.E. Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphates. Pharmacogenetics 2000, 10:767-779.
52. Machin A.F., Anderson P.H., Quick M.P., Woddel D.F., Skibniewska K.A., Howells L.C. The metabolism of diazinon in the liver and blood of species of varying susceptibility to diazinon poisoning. Xenobiotica 1976, 6:104.
53. Mackness B., Mackness M.I., Arrol T., Turkie W., Durrington P.N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modifications. FEBS Lett. 1998, 423:57-60.
54. Mackness B., Durrington P.N., Mackness M.I. Low paraoxonase in Persian Gulf War veterans self-reporting Gulf War syndrome. Biochem. Biophys. Res. Commun. 2000, 276:729-733.
55. Mackness B., Davies G.K., Turkie W., Lee E., Roberts D.M., Hill E., Roberts C., Durrington P.N., Mackness M.I. Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype?. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1451-1457.
56. Mackness B., Durrington P.N., Povey A., Thomson S., Dippnall M., Mackness M., Smith T., Cherry N. Paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep. Pharmacogenetics 2003, 13:81-88.
57. Mackness M.S., Mackness B., Durrington P.N. Paraoxonase and coronary heart disease. Artheroscler. Suppl. 2002, 3:49-55.
58. Main A.R. The role of A-esterase in the acute toxicity of paraoxon, TEEP and parathion. Can. J. Biochem. Physiol. 1956, 34:197-216.
59. Mazur A. An enzyme in animal tissue capable of hydrolyzing the phosphorus-fluorine bond of alkyl fluorophosphates. J. Biol. Chem. 1946, 164:271-289.
60. Mortensen S.R., Chanda S.M., Hooper M.J., Padilla S. Maturational differences in chlorpyrifos-oxonase activity may contribute to age-related sensitivity to chlorpyrifos. J. Biochem. Toxicol. 1996, 11:279-287.
61. Moser V.C., Chanda S.M., Mortensen S.R., Padilla S. Age- and gender-related differences in sensitivity to chlorpyrifos in the rat reflect developmental profiles of esterase activities. Toxicol. Sci. 1998, 46:211-222.
62. Mueller R.F., Hornung S., Furlong C.E., Anderson J., Giblett E.R., Motulsky A.G. Plasma paraoxonase polymorphism: A new enzyme assay, population, family, biochemical and linkage studies. Am. J. Hum. Genet. 1983, 35:393-408.
63. Murphy S.D. Toxicity and hepatic metabolism of organophosphate insecticides in developing rats. Banbury Rep. 1982, 11:125-136.
64. Padilla S., Buzzard J., Moser V.C. Comparison of the role of esterases in the differential age-related sensibility to chlorpyrifos and metamidophos. Neurotoxicology 2000, 21:49-56.
65. Playfer J.R., Eze L.C., Bullen M.F., Evans D.A. Genetic polymorphism and interethnic variability of plasma paraoxonase activity. J. Med. Genet. 1976, 13:337-342.
66. Pond A.L., Chambers H.W., Chambers J.E. Organophosphate detoxication potential of various rat tissues via A-esterase and aliesterase activities. Toxicol. Lett. 1995, 70:245-252.
67. Pope C.N., Chakraborti T.K. Dose-related inhibition of brain and plasma cholinesterase in neonatal and adult rats following sublethal organophosphate exposure. Toxicology 1992, 73:35-43.
68. Pope C.N., Liu J. Age-related differences in sensitivity to organophosphorus pesticides. Environ. Toxicol. Pharmacol. 1997, 4:309-314.
69. Richter R.J., Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999, 9:745-753.
70. Richter R.J., Jampsa R.L., Jarvik G.P., Costa L.G., Furlong C.E. Determination of paraoxonase 1 status and genotypes at specific polymorphic sites. Current Protocols in Toxicology 2004, 4.12.1-4.12.19. Wiley, New York. M. Maines, L.G. Costa, D.J. Reed, E. Hodgson (Eds.).
71. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
72. Serenson R.C., Bisgaier C.L., Aviram M., Hsu C., Billecke S., LaDu B.N. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: Apolipoprotein A-1 stabilizes activity. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2214-2225.
73. Sozmen E.Y., Mackness B., Sozmen B., Durrington P., Girgin F.K., Aslan L., Mackness M. Effect of organophosphate intoxication on human serum paraoxonase. Hum. Exp. Toxicol. 2002, 21:247-252.
74. Suehiro T., Nakamura T., Inoue M., Shiinoki T., Ikeda Y., Kumoin Y., Shindo M., Tanaka H., Hashimoto K. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 2000, 150:295-298.
75. Suzuki T., Morito H., Ono K., Mackawa K., Nagai R., Yazaki Y. Sarin poisoning in Tokyo subway. Lancet 1995, 345:980-981.
76. Yamada Y., Takatori T., Nagao M., Iwase H., Kurada N., Yanagida J., Shinozuka T. Expression of paraoxonase isoform did not confer protection from acute, sarin poisoning in the Tokyo subway terrorist attack. Int. J. Leg. Med. 2001, 115:82-84.
77. 192 isoform of paraoxonase with low sarinhydrolyzing activity is dominant in the Japanese. Hum. Genet. 1997, 101:67-68.
78. Zech R., Zurcher K. Organophosphate splitting serum enzymes in different mammals. Comp. Biochem. Physiol. B 1974, 48:427-433.